# Novartis AG: Form 20-F for the period ended Dec 31, 2018

- Company: [Novartis AG](/companies/nvs.md) (CIK 1114448)
- Form: 20-F
- Filed: 2019-01-30
- Accepted by EDGAR: Jan 30, 2019, 07:19 ET
- Period: 2018-12-31
- Accession: 0001370368-19-000002
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114448/000137036819000002/a19013020f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114448/000137036819000002/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 12 months, 2018-01-01 to 2018-12-31 | $18.41bn | ifrs-full:CostOfSales |
| Gross profit | 12 months, 2018-01-01 to 2018-12-31 | $34.76bn | ifrs-full:GrossProfit |
| Operating income | 12 months, 2018-01-01 to 2018-12-31 | $8.17bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2018-01-01 to 2018-12-31 | $1.22bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2018-01-01 to 2018-12-31 | $12.61bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2018-01-01 to 2018-12-31 | $5.38 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2018-01-01 to 2018-12-31 | $5.44 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2018-01-01 to 2018-12-31 | $14.27bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2018-01-01 to 2018-12-31 | $1.77bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2018-12-31 | $13.27bn | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2018-12-31 | $35.56bn | ifrs-full:CurrentAssets |
| Total assets | at 2018-12-31 | $145.56bn | ifrs-full:Assets |
| Current liabilities | at 2018-12-31 | $29.61bn | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2018-12-31 | $66.87bn | ifrs-full:Liabilities |
| Shareholders' equity | at 2018-12-31 | $78.61bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | at 2018-12-31 | 2,311,171,429 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1114448/000137036819000002/a19013020f.htm

Filed Jan 30, 2019.
Source: SEC EDGAR, the filing index for accession 0001370368-19-000002. Last ingested by Listed: Oct 27, 2026, 17:27 ET. No prices; not investment advice.